Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.22/9465 |
Resumo: | The growing and aging population has contributed to the increased prevalence of Alzheimer's disease (AD) and other types of dementia in the world. AD is a progressive and degenerative brain disease with an onset characterized by episodic memory impairments, although progressive deficits can be observed in several domains including language, executive functions, attention and working memory. The relationship between cognitive impairments and the topography and progression of brain neuropathology is well established. The pathophysiologic mechanisms and processes that underline the course of cognitive and clinical decline have been the theoretical support for the development of pharmacological treatments for AD. Cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) antagonists are the main drugs used in the management of global cognitive impairment and several studies also explore the effects of both in specific cognitive measures. Recent research trends also examine the effects of combination therapy using both compounds. This review aims to update practical recommendations for the treatment of global cognitive functioning and specific neurocognitive deficits in AD using ChEIs, NMDA antagonists and combination therapy with both drugs. |
id |
RCAP_bfc93fe152c96cfa3cd194d2c64c7705 |
---|---|
oai_identifier_str |
oai:recipp.ipp.pt:10400.22/9465 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological reviewAlzheimer DiseaseCholinesterase InhibitorsCognition DisordersHumansN-MethylaspartateThe growing and aging population has contributed to the increased prevalence of Alzheimer's disease (AD) and other types of dementia in the world. AD is a progressive and degenerative brain disease with an onset characterized by episodic memory impairments, although progressive deficits can be observed in several domains including language, executive functions, attention and working memory. The relationship between cognitive impairments and the topography and progression of brain neuropathology is well established. The pathophysiologic mechanisms and processes that underline the course of cognitive and clinical decline have been the theoretical support for the development of pharmacological treatments for AD. Cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) antagonists are the main drugs used in the management of global cognitive impairment and several studies also explore the effects of both in specific cognitive measures. Recent research trends also examine the effects of combination therapy using both compounds. This review aims to update practical recommendations for the treatment of global cognitive functioning and specific neurocognitive deficits in AD using ChEIs, NMDA antagonists and combination therapy with both drugs.Repositório Científico do Instituto Politécnico do PortoCampos, CarlosRocha, NunoVieira, Renata TelesRocha, Susana ATelles-Correia, DiogoPaes, FláviaYuan, TifeiNardi, Antonio EgidioArias-Carrión, OscarMachado, SergioCaixeta, Leonardo2017-01-26T17:09:52Z2016-032016-03-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/9465eng10400.22/9465metadata only accessinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-13T12:50:53Zoai:recipp.ipp.pt:10400.22/9465Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:30:04.523637Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review |
title |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review |
spellingShingle |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review Campos, Carlos Alzheimer Disease Cholinesterase Inhibitors Cognition Disorders Humans N-Methylaspartate |
title_short |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review |
title_full |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review |
title_fullStr |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review |
title_full_unstemmed |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review |
title_sort |
Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review |
author |
Campos, Carlos |
author_facet |
Campos, Carlos Rocha, Nuno Vieira, Renata Teles Rocha, Susana A Telles-Correia, Diogo Paes, Flávia Yuan, Tifei Nardi, Antonio Egidio Arias-Carrión, Oscar Machado, Sergio Caixeta, Leonardo |
author_role |
author |
author2 |
Rocha, Nuno Vieira, Renata Teles Rocha, Susana A Telles-Correia, Diogo Paes, Flávia Yuan, Tifei Nardi, Antonio Egidio Arias-Carrión, Oscar Machado, Sergio Caixeta, Leonardo |
author2_role |
author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Politécnico do Porto |
dc.contributor.author.fl_str_mv |
Campos, Carlos Rocha, Nuno Vieira, Renata Teles Rocha, Susana A Telles-Correia, Diogo Paes, Flávia Yuan, Tifei Nardi, Antonio Egidio Arias-Carrión, Oscar Machado, Sergio Caixeta, Leonardo |
dc.subject.por.fl_str_mv |
Alzheimer Disease Cholinesterase Inhibitors Cognition Disorders Humans N-Methylaspartate |
topic |
Alzheimer Disease Cholinesterase Inhibitors Cognition Disorders Humans N-Methylaspartate |
description |
The growing and aging population has contributed to the increased prevalence of Alzheimer's disease (AD) and other types of dementia in the world. AD is a progressive and degenerative brain disease with an onset characterized by episodic memory impairments, although progressive deficits can be observed in several domains including language, executive functions, attention and working memory. The relationship between cognitive impairments and the topography and progression of brain neuropathology is well established. The pathophysiologic mechanisms and processes that underline the course of cognitive and clinical decline have been the theoretical support for the development of pharmacological treatments for AD. Cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) antagonists are the main drugs used in the management of global cognitive impairment and several studies also explore the effects of both in specific cognitive measures. Recent research trends also examine the effects of combination therapy using both compounds. This review aims to update practical recommendations for the treatment of global cognitive functioning and specific neurocognitive deficits in AD using ChEIs, NMDA antagonists and combination therapy with both drugs. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-03 2016-03-01T00:00:00Z 2017-01-26T17:09:52Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.22/9465 |
url |
http://hdl.handle.net/10400.22/9465 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10400.22/9465 |
dc.rights.driver.fl_str_mv |
metadata only access info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
metadata only access |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131396771414016 |